The Human Genome Project completes the reading of DNA.
Dompé establishes a biotechnology plant in L’Aquila for the production of recombinant proteins to treat rare diseases.
In the centenary of the Nobel Prize, the American Leland H. Hartwell and the Britons R. Timothy Hunt and Paul M. Nurse receive the Nobel Prize in Physiology or Medicine for discovering key factors in cell cycle regulation.
Biogen Dompé, a joint venture between Biogen Idec and Dompé, is founded in Italy as a company dedicated to research into new treatments for multiple sclerosis with the aim of offering patients innovative biotechnological products with a high therapeutic profile.
Craig Venter and his collaborators create a complete DNA in a test tube, and subsequently make the first transplant of genetic material from one mycoplasma to another of a different species.
Amgen Dompé, a joint venture between Amgen and Dompé, is founded for the development of drugs to be used in oncology and nephrology. In 2014 the partners mutually agreed to conclude the JV.
Science makes it safe to reprogram skin cells so that they become stem cells without using cloning or destroying embryos. Furthermore, advances are made in the gene therapy of Leber’s congenital amaurosis, a severe eye disease.
Dompé creates its Q-rare Division with the aim of offering innovative therapeutic solutions for the treatment of orphan diseases.
Nature publishes a study of the effects of rapamycin, a drug that may represent a long-life elixir by acting on the metabolism.
Dompé acquires the right to develop, produce and market NGF for the treatment of neurotrophic keratitis, a rare eye disease. This is the first therapeutic application of the findings that led to Rita Levi Montalcini being awarded the Nobel Prize in Physiology or Medicine. Dompé also acquires more than 30% of Philogen, a biotech company involved in the development of oncological drugs.
Craig Venter creates “artificial life”: i.e. a cell made using synthetic, laboratory-constructed DNA that is capable of self-replication.
Dompé’s growth continues, and the extension of its biotech plant in L’Aquila increases its research and production potential.
Progress is made in controlling AIDS as a study demonstrates that drugs can reduce the probability of sexually transmitting the disease in 96% of seropositive people.
Research into use of stem cells continues. A study demonstrates that mouse embryonal stem cells allow the birth of animals to surrogate mothers.
New headquarters are opened in Milan, and Dompé completes the acquisition of Anabasis, an Italian company that develops innovative treatments for eye diseases starting from studies on NGF.
A study by researchers of the University of Washington shows that it will be possible to predict the entire genome of a fetus on the basis of a maternal sample and a paternal saliva sample.
A phase III trial designed to evaluate the efficacy of reparixin in improving the efficiency of allogeneic pancreatic islet transplantation is started in Europe and the USA.
Professor Rita Levi Montalcini, one of the most important scientists in modern medicine, dies in Rome at the age of 103 years.
The first international phase I/II clinical trial of the use of recombinant human NGF in the treatment of neurotrophic keratitis gets under way in 37 European centres.
The Nobel Prize in Physiology or Medicine is awarded to James Rothman, Randy Schekman and Thomas Südhof, three biologists who discovered the mechanism regulating the transport of molecules inside cells.
Dompé announces that rhNGF has been designated an orphan drug for the treatment of retinitis pigmentosa by the European Medicines Agency and the USA Food and Drug Administration.
The British Royal Society expects scientific production China will exceed that of the United States by the end of the year, seven years earlier than previously estimated.
A phase II/III trial designed to evaluate the efficacy and safety of reparixin in the autologous transplantation of pancreatic islets is started in the United States.
Fabiola Gianotti becomes the first woman to be selected as General Director in the 60-year history of the European Organisation for Nuclear Research (CERN).
Enrolment conclusion of the Dompé first phase III trial with reparixin in patients undergoing pancreatic islet transplantations.
Genetic engineering expands the genetic alphabet by synthesising an artificial bacterium that has two additional nucleic acids called X and Y. The two new "letters" can be used to create laboratory-made proteins with new amino acids.
Dompé inaugurates his New York subsidiary with the aim of strengthening the company presence in the USA and coordinate the Research&Development of new drugs for the treatment of diseases in the areas of ophthalmology, oncology and organ transplantation.